BioStem Technologies, Inc. (BSEM) Form 424B3 — Oct 13, 2026
BioStem Technologies filed a 424B3 prospectus registering the resale of up to 2,224,270 common shares by selling stockholders from its September 2026 private placement, including 735,296 shares sold at $4.08 plus shares underlying Series A and Series B warrants struck at $3.83, and 18,382 placement agent warrant shares.
Key figures
- Shares Offered
- 2224270
- Shares Outstanding
- 18672125
- Cef facility
- $40,000,000 committed equity facility with Roth Principal Investments
- Clearance payment due
- $10.0 million (unpaid, due Sept 15, 2026)
- Shares offered direct
- 735296
- Warrant exercise price
- 3.83
- Series a warrant shares
- 735296
- Series b warrant shares
- 735296
- Accumulated deficit 2025
- $21.2 million
- Closing price oct 12 2026
- 2.44
- Pro forma revenue 6m 2026
- 15521105
- Cms flat reimbursement rate
- $127.14 per square centimeter
- Placement agent fee percent
- 7.0% of gross proceeds
- Placement agent warrant shares
- 18382
- Private placement price per share
- 4.08
- Placement agent warrant exercise price
- 6.12
- Shares outstanding full warrant exercise
- 20896395
AI analysis
Red flags8 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.